ARS Pharmaceuticals (SPRY) Other Working Capital Changes (2020 - 2026)

ARS Pharmaceuticals has disclosed Other Working Capital Changes across 7 years of filings, most recently posting -$61000.0 for Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$61000.0, down 101.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.5 million (down 150.18% YoY), and the FY2025 annual result was -$656000.0, down 110.6% from the prior year.
• Other Working Capital Changes came in at -$61000.0 for Q1 2026 at ARS Pharmaceuticals, up from -$361000.0 in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $7.3 million in Q4 2024 to a low of -$4.1 million in Q2 2025.
• The 5-year median for Other Working Capital Changes is -$275000.0 (2022), against an average of $72928.6.
• Peak annual rise in Other Working Capital Changes reached 347.15% in 2023, while the deepest fall reached 3298.91% in 2023.
• ARS Pharmaceuticals' Other Working Capital Changes stood at -$189000.0 in 2022, then slumped by 1258.73% to -$2.6 million in 2023, then soared by 382.36% to $7.3 million in 2024, then plunged by 104.98% to -$361000.0 in 2025, then soared by 83.1% to -$61000.0 in 2026.
• The last three Other Working Capital Changes figures came in at -$61000.0 (Q1 2026), -$361000.0 (Q4 2025), and -$992000.0 (Q3 2025), per Business Quant data.